Kubitza, D., Becka, M., Voith, B., et al. (2005) Safety, Pharmacodynamics, and Pharmacokinetics of Single Doses of BAY 59-7939 an Oral, Direct Factor Xa Inhibitor. Clinical Pharmacology Therapeutics, 78, 412-421.
http://dx.doi.org/10.1016/j.clpt.2005.06.011

has been cited by the following article:

• TITLE: Thromboprophylaxis for Hip and Knee Arthroplasty: Current Managements and Review of the Literature

  AUTHORS: Ismail Hakki Korucu, Faik Turkmen, Burkay Kacira, Onur Bilge, Alper Kilicaslan, Serdar Toker

  KEYWORDS: Total Hip Arthroplasty, Total Knee Arthroplasty, Thromboprophylaxis

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.4 No.12, November 11, 2014

  ABSTRACT: Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) are major surgical procedures which can cause high morbidity and even mortality. Among these complications is venous thrombo embolism (VTE) comprising deep vien thrombosis (DVT) and pulmonary embolism (PE). Therefore, after these operations, thromboprophylaxis is routinely used. However, it has some complications such as bleeding, adverse effect of chemical agents for using prevention of DVT. Anti-thrombotic prophylaxis includes: low molecular weight heparin (LMWH), fondaparinux, apixaban, dabigatran, rivaroxaban, low dose unfractionated heparin (LDUH), adjusted dose vitamin K antagonist (VKA), aspirin, or mechanical thromboprophylaxis devices. All over the World, orthopaedic surgeons consider a balance between thromboprophylaxis and bleeding. However, it has been still controversy about optimum prophylaxis for DVT. In this current paper, we aimed to review the literature under light of the current studies.